Delving into the Latest Updates on TQB-3909 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

Bcl-2

Mechanism

Bcl-2 inhibitors(Apoptosis regulator Bcl-2 inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [2]

Active Indication

Mantle cell lymphoma recurrentMantle cell lymphoma refractoryMyelofibrosis+ [12]

Inactive Indication-

Originator Organization

Nanjing Shunxin Pharmaceutical Co., Ltd.

Active Organization

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Nanjing Shunxin Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Primary objective: To evaluate the effectiveness of TQ05105 tablets combined with TQB3909 tablets in the treatment of intermediate- and high-risk myelofibrosis (MF). Secondary objective: To evaluate the safety and improvement of related symptoms of TQ05105 tablets combined with TQB3909 tablets in the treatment of intermediate- and high-risk MF subjects.

Start Date09 Mar 2024

Sponsor / Collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

100 Clinical Results associated with TQB-3909

Login to view more data

100 Translational Medicine associated with TQB-3909

Login to view more data

100 Patents (Medical) associated with TQB-3909

Login to view more data

100 Deals associated with TQB-3909

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Primary Myelofibrosis	Phase 2	CN	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	13 May 2024
Acute Myeloid Leukemia	Phase 2	CN	Nanjing Shunxin Pharmaceutical Co., Ltd.	25 Apr 2024
Myelodysplastic Syndromes	Phase 2	CN	Nanjing Shunxin Pharmaceutical Co., Ltd.	25 Apr 2024
Myeloid Tumor	Phase 2	CN	Nanjing Shunxin Pharmaceutical Co., Ltd.	25 Apr 2024
Chronic Lymphocytic Leukemia	Phase 2	CN	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	11 Oct 2023
Small Lymphocytic Lymphoma	Phase 2	CN	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	11 Oct 2023
Mantle cell lymphoma recurrent	Phase 2	CN	Nanjing Shunxin Pharmaceutical Co., Ltd.	20 Sep 2023
Mantle cell lymphoma refractory	Phase 2	CN	Nanjing Shunxin Pharmaceutical Co., Ltd.	20 Sep 2023
Advanced breast cancer	Phase 2	CN	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	02 Mar 2023
HR Positive/HER2 Negative/Node positive breast cancer	Phase 2	CN	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	02 Mar 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04975204 (TQB3909-I-01, ESMO2024) Manual	Phase 1	Acute Myeloid Leukemia \| Non-Hodgkin Lymphoma	69	TQB3909 (CLL/SLL)	(uwrzdwsiim) = None fbzzgdfssu (twvyacxcgd ) View more	Positive	13 Sep 2024
				TQB3909 (B-NHL)